Company Overview - Ooma is a multi-tenant SaaS platform for telephony, messaging, video, and more, serving over 1.2 million core users[8] - The company's annual exit recurring revenue (AERR) is $243 million, with a recurring gross profit margin of 72%[8] - Ooma boasts a 99% net dollar subscription retention rate (NDR)[8] Financial Performance - Ooma's revenue is $264 million, with adjusted EBITDA of $29 million[8] - The company targets a long-term subscription & services gross margin of 75%-78%[62] - Ooma's target model includes a long-term adjusted EBITDA margin of 20%-25% of revenue[62] Market Opportunity - The worldwide hosted voice/UC public cloud (UCaaS) market is projected to grow at a CAGR of 7% from $23 billion in 2023 to $32 billion in 2028[28] - The North American business market has 57 million business lines[28] - Ooma addresses a >10 million line U S market opportunity in POTS (copper line) replacement[40]

TERN-701 Efficacy and Safety - TERN-701 demonstrated a 64% Major Molecular Response (MMR) achievement rate at 24 weeks across all doses in non-T315I CP-CML patients (N=38)[20, 26] - At doses ≥320 mg QD, TERN-701 achieved a 75% MMR rate and a 36% Deep Molecular Response (DMR) rate at 24 weeks[18, 26, 75] - The majority of Treatment-Emergent Adverse Events (TEAEs) were low grade, with Grade 3 AEs less than 10%[18, 26] - No Dose Limiting Toxicities (DLTs) were observed, and the Maximum Tolerated Dose (MTD) was not identified[26, 37] - The study observed no pancreatic toxicity or clinically significant changes in blood pressure[18, 26] Patient Population and Treatment - The CARDINAL study enrolled a predominantly 3L+ refractory CML population (N=63 as of September 13, 2025)[24] - 38% of patients had prior asciminib treatment, with 75% of those discontinuing due to lack of efficacy[26, 33] - 87% of patients remained on treatment with a median treatment duration of 6.1 months[35] Competitive Landscape and Future Development - Asciminib NBRx share in 2L is 52% and in 3L+ is 53%[7] - Asciminib NBRx share of front-line is 22%[7] - TERN-701 is positioned to potentially capture new patients and switch from both Asciminib and Active Site TKIs[103] - Multiple catalysts are planned in 2026, including expanded CARDINAL data, pivotal dose selection, and alignment with regulators for pivotal studies[99, 106]

VIEW SHARE Netflix and Warner Bros. combined will have 9.2% TV viewshare in the U.S. Nielsen Share of U.S. TV Time By Distributor 1 October 2025 October 2025 Pro Forma YouTube The Walt Disney Company Netflix & Warner Bros. NBCUniversal FOX Paramount Discovery Global 12.9% 11.4% 9.2% 8.6% 4.4% 8.4% 8.2% 1.2% HBO / HBO Max YouTube 12.9% The Walt Disney Company NBCUniversal FOX Paramount Netflix 11.4% 8.6% 8.4% 8.0% 5.6% 8.2% Warner Bros. Discovery 1.2% HBO / HBO Max ...

NYSE-A:CTGO TSX-V:DV | NYSE-A:DVS MERGER TO CREATE A NEW NORTH AMERICAN HIGH-GRADE, MID-TIER SILVER & GOLD PRODUCER AND DEVELOPER I N V E S T O R P R E S E N TAT I O N D E C E M B E R 2 0 2 5 W W W . C O N T A N G O O R E . C O M W W W . D O L L Y V A R D E N S I L V E R . C O M DISCLAIMER LEGAL DISCLAIMER The information contained in this presentation furnished by or on behalf of Dolly Varden Silver Corporation ("Dolly Varden") or Contango ORE, Inc. ("Contango") has been prepared in respect of the proposed ...

Ziftomenib + Ven/Aza in Newly Diagnosed NPM1-m AML - In newly diagnosed NPM1-m AML patients, the combination of ziftomenib 600 mg QD with Ven/Aza resulted in a composite complete remission (CRc) rate of 86% (32/37), with a complete remission (CR) rate of 73% (27/37)[35] - Among CRc responders in newly diagnosed NPM1-m AML, 68% (17/25) achieved MRD negativity at a threshold of ≤01% and 44% (11/25) at a threshold of ≤001%[36] - In newly diagnosed NPM1-m AML, 68% (27/40) of patients remained alive and continued on study after a median follow-up of 261 weeks[40] Ziftomenib + Ven/Aza in R/R NPM1-m or KMT2A-r AML - In R/R NPM1-m AML patients, the combination of ziftomenib 600 mg with Ven/Aza resulted in an overall response rate (ORR) of 65% (31/48) and a CRc rate of 48% (23/48)[57] - In R/R KMT2A-r AML patients, the combination of ziftomenib 600 mg with Ven/Aza resulted in an ORR of 41% (13/32) and a CRc rate of 28% (9/32)[57] - Among R/R NPM1-m AML patients without prior venetoclax exposure, the CRc rate was 70% (16/23) and the ORR was 83% (19/23)[58] - Among R/R KMT2A-r AML patients without prior venetoclax exposure, the CRc rate was 60% (6/10) and the ORR was 70% (7/10)[58] - For R/R NPM1-m AML, the median duration of CRc was 399 weeks after a median follow-up of 274 weeks[61] - For R/R KMT2A-r AML, the median duration of CRc was 124 weeks after a median follow-up of 169 weeks[64]

Paramount's $30 all-cash offer provides greater value and certainty to WBD shareholders December 8, 2025 Disclaimer This presentation is provided for informational purposes only and for no other purpose. Certain information contained herein has been obtained from published sources prepared by third parties that Paramount Skydance Corporation ("Paramount") believes to be reliable. Moreover, certain information in this presentation is based on assumptions, estimates and other factors that were available to Pa ...

Acquisition Overview - Home BancShares, Inc (HOMB) is acquiring Mountain Commerce Bancorp, Inc (MCBI)[1] - The transaction is expected to be accretive to EPS, BVPS, and TBVPS[5] - The deal provides HOMB with a meaningful entrance into high-growth Knoxville, Nashville, and Johnson City MSAs[5] - The transaction is financially compelling and low-risk, with conservative assumptions for credit mark, one-time costs, and expense savings[5] Transaction Terms - The consideration mix is 100% HOMB stock[7,18] - The implied price per share is $2351[18] - The aggregate transaction value is $1501 million[18] - The price/TBV is 105%[18] - The price/2026E EPS is 81x[18] Financial Highlights of MCBI - MCBI has $18 billion in assets[6] - MCBI has $16 billion in deposits[6] - MCBI has $15 billion in gross loans[6,7] - MCBI's average ROAA from 2021-2024 was 102%[6] - MCBI's average ROATCE from 2021-2024 was 123%[6] - MCBI's efficiency ratio is 552%[6] - MCBI's YoY NIM expansion was 43 bps[6] Pro Forma Impact - The acquisition is expected to increase ROATCE by +35bps[20] - 2026E EPS accretion is projected to be 14%[20] - 2027E EPS accretion is projected to be 30%[20] - BVPS accretion is projected to be 07%[20] - TBVPS accretion is projected to be 02%[20] - The CET1 ratio at closing is projected to be 159%[20] - The total capital ratio at closing is projected to be 185%[20]

Financial Status & Milestones - Theravance Biopharma had approximately $333 million in cash with no debt and expects to remain at similar levels in Q4 2025 [7] - The company anticipates $175 million in near-term milestones based on TRELEGY and YUPELRI sales [7] - Theravance Biopharma has a 35% U S profit share with Viatris for YUPELRI, with IP protection into 2039 [7] Ampreloxetine & CYPRESS Trial - Ampreloxetine targets approximately 40,000 underserved patients in the U S with symptomatic nOH due to MSA [7] - The Phase 3 CYPRESS trial completed enrollment in Q3 2025, with topline data expected in Q1 2026 [7] - In a REDWOOD pre-specified MSA subgroup analysis (n=40), the greatest difference was observed in the 6-item OHSA composite score [48, 51] - Approximately 70-80% of patients with MSA will develop nOH in their lifetime, and despite treatment with available pressor agents, 68% remain symptomatic [30] Commercial Opportunity - The U S market includes approximately 40,000 MSA patients with nOH [7, 83, 96] - Only approximately 34% of patients are currently treated, indicating a significant unmet need [84] - The average launch price for chronic neurology therapies is approximately $333,000 [111]

Acquisition Overview - Infinity Natural Resources (INR) 将以 12 亿美元的总价全现金收购 Antero 在俄亥俄州的 Utica Shale 资产中未分割的 51% 权益[3,4] - 该交易预计将在 2026 年第一季度完成，收购价格约为 NTM 调整后 EBITDAX 的 4.7 倍，2027 年预计调整后 EBITDAX 的 3.6 倍[4,13,14] - 收购的资产包括约 70,900 英亩的净水平面积，超过 110 个未开发的位置，以及约 141 英里的高低压集气管线，系统吞吐能力为 600 mmcf/d[4] Strategic Benefits - 收购后，INR 将控制俄亥俄州 Utica Shale 中约 102,000 英亩的净面积，未开发的净储量约为 1.4 Tcfe，使 INR 在俄亥俄州 Utica Shale 的地位显著提升（约 50% 的面积增长）[5,38] - 收购的 Midstream 资产包括约 141 英里的集气管线，吞吐能力为 600 mmcf/d，以及约 90 英里的水管线，降低了成本和现金盈亏平衡点[7,40] - 预计仅在 2026 年就可实现约 2500 万美元的协同效应，这主要得益于较低的运营成本和互补的土地位置[8,41] Financial Impact - 该收购预计将立即增加利润率、每股现金流、每股自由现金流和每股净资产价值[9,42] - 该公司预计到 2027 年底，净杠杆率将低于 1.0 倍[10,43]

Aura Day 2025 D E C E M B E R 2 0 2 5 To find, mine and provide the most important and essential ores that allow the world and mankind to create, innovate and prosper. Aura Day team Seasoned Management Team Glauber Luvizotto Isabela Dumont Head People, Communications & Sustainability Natasha Utescher Head of IR and Treasury Frederico Silva Director of Operations Aura Borborema, Brazil Francisco do Carmo Director of Operations Aura Minosa, Honduras Pitágoras Costa Director of Projects and Construction Richar ...